Gladstone Institutes

2017–2022 · research · RF1

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$188.8kAmyotrophic Lateral Sclerosis Research

2017–2021 · grant · MSRP

Fibrin as an Inhibitor of Remyelination: Mechanisms, Functions, and Therapeutic Applications in Multiple Sclerosis

Katerina Akassoglou · Gladstone Institutes · funded by Congressionally Directed Medical Research Programs

$1.1M

2017–2022 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$424.8kCRISPR and Genetic Engineering

2017–2022 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$412.1kCRISPR and Genetic Engineering

2017–2022 · research · R01

Assessing the root causes of chronic inflammation in HIV-infected individuals using drugs of abuse

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

$714.5kTryptophan and brain disorders

2017–2022 · research · R01

ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease

Yadong Huang · Gladstone Institutes · funded by National Institutes of Health

$875.7kAlzheimer's disease research and treatments

2017–2021 · research · R37

Rare Variant Whole Genome Analysis and iPSC Validation of Putative Genetic Modifiers of Huntington Disease

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$615.5kGenetic Neurodegenerative Diseases

2017–2022 · research · RF1

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$188.8kAmyotrophic Lateral Sclerosis Research

2017–2022 · research · R01

ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease

Yadong Huang · Gladstone Institutes · funded by National Institutes of Health

$853.5kAlzheimer's disease research and treatments

2017–2022 · research · RF1

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$188.8kAmyotrophic Lateral Sclerosis Research

2017–2022 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$424.8kCRISPR and Genetic Engineering

2017–2024 · research · R37

Rare Variant Whole Genome Analysis and iPSC Validation of Putative Genetic Modifiers of Huntington Disease

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$643.8kGenetic Neurodegenerative Diseases

2017–2022 · research · RF1

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$3.2MAmyotrophic Lateral Sclerosis Research

2017–2020 · grant · PRMRP

Molecular Mechanisms of Transcription Factor Dosage in Heart Development and Congenital Heart Disease

Benoit Bruneau · Gladstone Institutes · funded by Congressionally Directed Medical Research Programs

$2.3M

2017–2021 · research · R37

Rare Variant Whole Genome Analysis and iPSC Validation of Putative Genetic Modifiers of Huntington Disease

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$643.8kGenetic Neurodegenerative Diseases

2017–2019 · training · Predoctoral Fellowship

The Influence of the Fetal Cardiac Extracellular Matrix on Cardiomyocyte Proliferation

Mara Kauss · Gladstone Institutes · funded by American Heart Association

$53.7k

2017–2018 · grant · S10

Automated Slide Scanner with Brightfield and Fluorescence for Stereology, FISH and Brain Connectivity Mapping

Meredith Emily Kennedy Calvert · Gladstone Institutes · funded by National Institutes of Health

$264.8k

2017–2021 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$472.5k

2017–2021 · research · R01

Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$472k

2017–2022 · research · R01

Assessing the root causes of chronic inflammation in HIV-infected individuals using drugs of abuse

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

$714.5kTryptophan and brain disorders

2017–2022 · program · P01

Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

$1.7MHIV Research and Treatment

2017–2022 · research · R01

Study ApoE4's Effects on Hippocampal Network Activity in Alzheimer's Disease

Yadong Huang · Gladstone Institutes · funded by National Institutes of Health

$711.5k

2017–2024 · research · R01

Assessing the root causes of chronic inflammation in HIV-infected individuals using drugs of abuse

Melanie Maria Ott · Gladstone Institutes · funded by National Institutes of Health

$714.5kTryptophan and brain disorders

2017–2022 · research · RF1

Roles of ApoE4 in Brain Aging and Alzheimer's Disease

Yadong Huang · Gladstone Institutes · funded by National Institutes of Health

$3.3M

2017–2022 · research · RF1

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$188.8kAmyotrophic Lateral Sclerosis Research

2017–2022 · program · P01

Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

$1.7M

2017–2021 · research · R37

Rare Variant Whole Genome Analysis and iPSC Validation of Putative Genetic Modifiers of Huntington Disease

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$607.5kGenetic Neurodegenerative Diseases

2017–2022 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$424.8kCRISPR and Genetic Engineering

2017–2022 · research · R01

Therapeutic genome editing to treat Best disease

Bruce R Conklin · Gladstone Institutes · funded by National Institutes of Health

$424.8kCRISPR and Genetic Engineering

2017–2022 · program · P01

Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

$1.8M

2017–2019 · fellowship · Alzheimer's Disease Research: Postdoctoral Fellowship

Apolipoprotein E4: Mitochondrial Function and Alzheimer’s Disease

Chaeyoung Kim · Gladstone Institutes · funded by BrightFocus Foundation

$100k

2017–2023 · program · P01

Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruption

Satish Kumar Pillai · Gladstone Institutes · funded by National Institutes of Health

2017–2023 · program · P01

Project 2: Delineating virus and host cell-derived biomarkers predicting time to HIV rebound after treatment interruption

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

2017–2023 · program · P01

Core B: Bioinformatics/Biostatistics Core

Katherine S. Pollard · Gladstone Institutes · funded by National Institutes of Health

2017–2023 · program · P01

Project 1: Using CyTOF to identify phenotypic and functional biomarkers predicting time to HIV rebound after treatment interruption

Nadia R Roan · Gladstone Institutes · funded by National Institutes of Health

2017–2023 · program · P01

Core A: Administrative Core

Warner C. Greene · Gladstone Institutes · funded by National Institutes of Health

2016–2018 · research · R21

TRAP1 and FOXO1 as modifiers of progranulin and FTLD

Steven M Finkbeiner · Gladstone Institutes · funded by National Institutes of Health

$236.6kAmyotrophic Lateral Sclerosis Research

2016 · fellowship · Scientist Development Grant

Targeting WNT and TGF-B signaling to enhance direct cardiac reprogramming

Tamer Mohamed · Gladstone Institutes · funded by American Heart Association

$231k

2016–2021 · cooperative agreement · UH3

Effect of Aging on Efficacy of Alzheimer-focused Therapeutic Strategies

Lennart Mucke · Gladstone Institutes · funded by National Institutes of Health

$162.1kAlzheimer's disease research and treatments

2016–2019 · fellowship · F32

Reactivation of Innate Immune Response Pathways as Treatment for HIV Infection

Robyn Midori Kaake · Gladstone Institutes · funded by National Institutes of Health

$56.1kHIV Research and Treatment